论文部分内容阅读
目的 分析前列地尔联合复方鳖甲软肝片治疗慢性乙型肝炎肝硬化的临床效果.方法 从2018年4月～2020年2月来本院接受慢性乙型肝炎治疗的患者中抽取84例作为样本,按入院顺序分作两组,42例仅滴注前列地尔药物的患者设为对照组,42例于前者药物使用的基础上同期服用复方鳖甲软肝片的患者设为观察组.利用统计学软件对慢性乙型肝炎肝硬化患者治疗后的肝功能及药物治疗数据进行处理以获得研究结果.结果 两组患者在药物有效率及治疗后的肝功能指标方面,数值差异具有统计学意义(P ＜ 0.05),说明观察组更优;两组患者在用药不良反应发生率及治疗前的肝功能指标方面,数值差异不存在统计学意义(P ＞ 0.05).结论 对慢性乙型肝炎肝硬化患者给予前列地尔滴注的基础上同期服用复方鳖甲软肝片,可改善肝功能,提高用药效果.“,”Objective To analyze the clinical effect of alprostadil combined with compound Biejiaruangan tablets in the treatment of chronic hepatitis B cirrhosis. Methods 84 cases of patients with chronic hepatitis B in our hospital from April 2018 to February 2020 were selected as samples and divided into two groups according to the order of admission. 42 patients who only received alprostadil were set as the control group, and 42 patients who took Compound Biejia Ruangan tablets on the basis of the former drug use were set as the observation group. Statistical software was used to process the liver function and drug treatment data of patients with chronic hepatitis B cirrhosis after treatment to obtain the research results. Results Two groups of patients in the drug efficiency and liver function index after treatment, the numerical difference was statistically significant (P＜0.05), indicating that the observation group was better; the two groups of patients in the drug adverse reaction rate and liver function index before treatment, the numerical difference was small, there was no statistical significance(P＞0.05). Conclusion On the basis of alprostadil infusion, Compound Biejia Ruangan tablets can improve the liver function and improve the drug effect in patients with chronic hepatitis B cirrhosis.